vB_Ent31 bacteriophage may combat Enterobacter cloacae infections with macrophage modulating activity

IF 2.8 3区医学 Q3 VIROLOGY

Virology Pub Date : 2025-02-25 DOI:10.1016/j.virol.2025.110463

Mengyuan Li , Jiayue Ma , Xiaoshuang Feng , Naijin Zheng , Hong Li , Xue Chi , Xiang Ma , Yanqiong Tang , Juanjuan Li , Zhu Liu

{"title":"vB_Ent31 bacteriophage may combat Enterobacter cloacae infections with macrophage modulating activity","authors":"Mengyuan Li , Jiayue Ma , Xiaoshuang Feng , Naijin Zheng , Hong Li , Xue Chi , Xiang Ma , Yanqiong Tang , Juanjuan Li , Zhu Liu","doi":"10.1016/j.virol.2025.110463","DOIUrl":null,"url":null,"abstract":"<div><div>Multidrug-resistant organisms (MDRO), including MDR <em>Enterobacter</em> cloacae, may emerge due to the extensive usage of antibiotics and threaten the lives of millions of people around the world. Developing new antibiotic-free strategies to combat <em>E. cloacae</em> infections and curb the spread of drug-resistant genes is crucial. Bacteriophage therapy has garnered widespread attention as a promising approach to tackle bacterial infections. Herein, we isolated a specific bacteriophage (vB_Ent31) targeting <em>E. cloacae</em> from sewage using <em>E. cloacae</em> Ent31 as the host bacterium. vB_Ent31 is a tadpole-like phage with double-stranded DNA belonging to the <em>Siphoviridae</em> family. It exhibits narrow-spectrum activity against <em>Enterobacter</em> spp. and remains stable across a temperature range of 4–50 °C and pH 4 to 11. Significantly, vB_Ent31 prevents proliferation of Ent31 and inhibits inflammation, which further accelerate wound healing. Our findings suggest that bacteriophage therapy could offer an alternative to combating drug-resistant bacteria.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"605 ","pages":"Article 110463"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225000753","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Multidrug-resistant organisms (MDRO), including MDR Enterobacter cloacae, may emerge due to the extensive usage of antibiotics and threaten the lives of millions of people around the world. Developing new antibiotic-free strategies to combat E. cloacae infections and curb the spread of drug-resistant genes is crucial. Bacteriophage therapy has garnered widespread attention as a promising approach to tackle bacterial infections. Herein, we isolated a specific bacteriophage (vB_Ent31) targeting E. cloacae from sewage using E. cloacae Ent31 as the host bacterium. vB_Ent31 is a tadpole-like phage with double-stranded DNA belonging to the Siphoviridae family. It exhibits narrow-spectrum activity against Enterobacter spp. and remains stable across a temperature range of 4–50 °C and pH 4 to 11. Significantly, vB_Ent31 prevents proliferation of Ent31 and inhibits inflammation, which further accelerate wound healing. Our findings suggest that bacteriophage therapy could offer an alternative to combating drug-resistant bacteria.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology 医学-病毒学

CiteScore

6.00

自引率

0.00%

发文量

157

审稿时长

50 days

期刊介绍： Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.